Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 6/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.33 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16710170 | 0.86 | PIM1 (0.43) | PIM1PIM3CLK4MAPTROCK2 | |
| SCHEMBL14152978 | 0.82 | MAPT (0.42) | MAPTROCK2TNKSPARP1ROCK1 | |
| SCHEMBL10760551 | 0.69 | PIM1 (0.46) | PIM1PIM3CLK4MAPTPARP1 | |
| SCHEMBL17979374 | 0.69 | PTGDR2 (0.39) | PARP1PARP3 | |
| SCHEMBL5862985 | 0.66 | MAOB (0.51) | — | |
| SCHEMBL3976914 | 0.65 | MAPT (0.63) | CLK4MAPTPDE3BPDE3APARP1 | |
| SCHEMBL11062191 | 0.64 | KCNA3 (0.58) | HDAC1HDAC2 | |
| SCHEMBL4420937 | 0.64 | ALDH1A1 (0.65) | MAPTPDE3AEPHX2 | |
| SCHEMBL692156 | 0.63 | MAPT (0.56) | PIM1PIM3CLK4MAPTPDE3B | |
| SCHEMBL8108278 | 0.63 | MAPT (0.47) | MAPTROCK2TNKSPARP1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598372-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| US-9115114-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | PIM1 2186/4885PIM3 2314/4885CLK4 2431/4885 |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | PIM1 2186/4885PIM3 2314/4885CLK4 2431/4885 |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | PIM1 2186/4885PIM3 2314/4885CLK4 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.